Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(20/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(20/week)
News
United States
(450/week)
Manufacturing
(348/week)
Technology
(352/week)
Energy
(230/week)
Other Manufacturing
(292/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Novartis Pharmaceuticals Corporation
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Oct 02, 2019
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Sep 02, 2019
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Jun 03, 2019
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Jun 01, 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
May 24, 2019
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
May 07, 2019
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
May 05, 2019
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Apr 15, 2019
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
Mar 27, 2019
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mar 16, 2019
Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
Jan 28, 2019
Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
Jan 08, 2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Dec 02, 2018
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
Dec 01, 2018
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Nov 14, 2018
Novartis to fund five innovative ideas to support patients and the sickle cell community
Nov 11, 2018
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Nov 02, 2018
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
‹‹
Page 2
››
Latest News
Mar 29, 2024
dynaCERT Provides Update on the Purchase Order for HydraGEN™ Units Destined for Guyana
Mar 29, 2024
CFIUS Accepts Re-filed Notice for Proposed Sale of The Kinetic Group to CSG
Mar 29, 2024
Cheniere Energy Partners, L.P. 2023 Annual Report
Mar 29, 2024
Aptiv to Release First Quarter 2024 Financial Results
Mar 29, 2024
Empire State Realty Trust Receives WELL Health-Safety Leadership Award; Becomes Among the First Commercial...
Mar 29, 2024
Fortive Schedules First Quarter 2024 Earnings Conference Call
Mar 29, 2024
Pacific Coast Oil Trust Announces There Will Be No March Cash Distribution
Mar 29, 2024
Xylem to Release First Quarter 2024 Financial Results on May 2, 2024
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events